Overall survival. (A) OS curve for the combined cohort of 442 patients censored for HSCT, 88.4% at a median time to follow-up of 3.6 years (1320 days). (B) Kaplan-Meier survival curve depicting worse OS in HLA alloimmunized vs nonimmunized patients, P = .007. (C) Kaplan-Meier survival curves of patients segregated by sex and HLA alloimmunization status. Alloimmunized male patients had the worst reported OS, P = .004. (D) Kaplan-Meier survival curves at median survival time (1320 days): HLA class I Ab-negative nonresponders = 71.3%; HLA class I Ab-positive nonresponders = 51.4%; HLA class I Ab-negative responders = 96.3%; HLA class I Ab-positive responders = 93.5%. Statistically significant difference in OS between nonresponders to IST with HLA class 1 Ab-positive (pink curve) compared to responders with HLA class I Ab (blue curve), 51.4% vs 93.5%; P= .002. No difference in the OS between nonresponders regardless of HLA alloimmunization; P = .1. Pos, positive; Neg, negative.